Physician profile
Kristin E Symon
NPI 1811243090
$3,730.69
in general payments reported to CMS, 2019-2025
30 companies · $473 in 2025
The $473 reported for 2025 was more than what 76% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $697 · 2020: $371 · 2021: $327 · 2022: $658 · 2023: $848 · 2024: $356 · 2025: $473.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,677.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,676.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $426.77 | 2019-2025 | Cequa |
| Bausch & Lomb Americas INC. | $407.75 | 2022-2025 | Vyzulta, Miebo, Xiidra |
| Johnson & Johnson Surgical Vision, INC. | $322.47 | 2020-2025 | Amo Phaco Needle, Tecnis Iol, Tecnis Iol |
| Biotissue Holdings INC. | $287.47 | 2019-2023 | |
| Alcon Vision LLC | $224.80 | 2020-2025 | Rocklatan, Clareon, Tryptyr |
| Allergan, INC. | $213.57 | 2019-2022 | |
| Oyster Point Pharma, INC. | $200.85 | 2022-2024 | Tyrvaya |
| Dompe US, INC. | $199.90 | 2019-2025 | Oxervate |
| Novartis Pharmaceuticals Corporation | $174.71 | 2019-2022 | |
| Abbvie INC. | $168.52 | 2022-2023 | Vuity, Alphagan P, Lumigan |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $161.54 | 2019-2020 | |
| Coopervision INC. | $114.37 | 2020-2022 | |
| Sight Sciences, INC. | $91.83 | 2019-2022 | |
| Amgen INC. | $79.27 | 2024 | Tepezza |
| Eyevance Pharmaceuticals LLC | $74.54 | 2021-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $73.33 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $70.27 | 2024-2025 | Xdemvy |
| Johnson & Johnson Vision Care, INC. | $68.58 | 2020-2022 | |
| Harrow Eye, LLC | $47.21 | 2025 | Vevye |
| Horizon Therapeutics Plc | $38.85 | 2019-2020 | |
| Carl Zeiss Meditec, INC. | $36.82 | 2019 | |
| Thea Pharma INC. | $36.44 | 2023 | Iyuzeh |
| Mallinckrodt Hospital Products INC. | $31.79 | 2021 | |
| Rxsight INC | $31.54 | 2022-2025 | Rxsight Contact Lens, Rxsight Injector Cartridge, Light Adjustable Lens (Lal) |
| Astellas Pharma US INC | $30.89 | 2025 | Izervay |
| Optos, INC. | $27.76 | 2020 | |
| Abb Con-Cise Optical Group LLC | $23.30 | 2019 | |
| Aerie Pharmaceuticals, INC. | $22.56 | 2020 | |
| Alcon Research LLC | $22.55 | 2019 | |
| Shire North American Group INC | $20.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristin Symon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.